| Drug Name |
Talazoparib |
| Drug ID |
BADD_D02485 |
| Description |
Talazoparib was approved by the FDA for use in germline BRCA mutated, HER2 negative, locally advanced or metastatic breast cancer on October 16, 2018 under the trade name Talzenna [L4661]. Talzenna was granted approval based on the results of the EMBRACA trial in which talazoparib resulted in a mean 8.6 months progression-free survival time versus physician's choice chemotherapy which resulted in 5.6 months progression-free survival. |
| Indications and Usage |
Talazoparib is indicated for the treatment of deleterious or suspected deleterious germline BRCA mutated, HER2 negative locally advanced or metastatic breast cancer in adults [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XK04 |
| DrugBank ID |
DB11760
|
| KEGG ID |
D10732
|
| MeSH ID |
C586365
|
| PubChem ID |
135565082
|
| TTD Drug ID |
D0GV8J
|
| NDC Product Code |
46014-0350; 0069-1195; 0069-1235; 0069-1031; 63539-051; 63539-295; 46014-3130; 0069-1751; 46014-1140; 46014-0370; 46014-0360; 46014-3120; 0069-1501; 0069-0296 |
| UNII |
9QHX048FRV
|
| Synonyms |
talazoparib | Talzenna | BMN 673 | BMN-673 | BMN673 |
